Syros Pharmaceuticals - Stock Price History | SYRS

Historical daily share price chart and data for Syros Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Syros Pharmaceuticals as of October 26, 2021 is 4.18.
  • The all-time high Syros Pharmaceuticals stock closing price was 23.75 on August 07, 2017.
  • The Syros Pharmaceuticals 52-week high stock price is 15.65, which is 274.4% above the current share price.
  • The Syros Pharmaceuticals 52-week low stock price is 4.00, which is 4.3% below the current share price.
  • The average Syros Pharmaceuticals stock price for the last 52 weeks is 7.26.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Syros Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 9.0796 7.1300 14.6600 4.4600 10.8500 57.02%
2019 7.3656 5.9200 11.6500 4.5200 6.9100 24.06%
2018 10.6333 9.9800 13.6500 5.5550 5.5700 -42.75%
2017 15.0496 12.4800 23.7500 8.4500 9.7300 -19.98%
2016 13.3876 18.1500 19.3500 8.5100 12.1600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.259B $0.015B
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86